pp-263 Tablets
Dossier type
US CTD
Dossier status
Under development
Country of origin
United States
GMP approvals
FDA
Comments
Indication: Neurological disease, Central nervous system disease, Neurodegenerative disease, Movement disorder, Neuromuscular disease
Clinical stage: Phase 2
Modality: Small molecule
Mechanism & Target: Not disclosed
Route & form: Oral
Differentiation: Across two independent Phase 2 studies, product has demonstrated convergent, mechanistically coherent signals spanning.
Manufacturer #39677
A clinical-stage biopharmaceutical company focused on neurology. Developing a small molecule therapeutic targeting neurology with global development focus. Pipeline positioned for regulatory advancement in key markets.
None